MeiraGTx (MGTX) Competitors $8.37 +0.30 (+3.72%) Closing price 04:00 PM EasternExtended Trading$8.34 -0.03 (-0.42%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGTX vs. VCEL, NAMS, DNLI, KNSA, RXRX, APGE, CGON, AGIO, INDV, and IRONShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Vericel (VCEL), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Indivior (INDV), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. MeiraGTx vs. Its Competitors Vericel NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Apogee Therapeutics CG Oncology Agios Pharmaceuticals Indivior Disc Medicine Vericel (NASDAQ:VCEL) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Do analysts recommend VCEL or MGTX? Vericel currently has a consensus price target of $61.14, indicating a potential upside of 47.33%. MeiraGTx has a consensus price target of $24.00, indicating a potential upside of 186.74%. Given MeiraGTx's higher probable upside, analysts clearly believe MeiraGTx is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, VCEL or MGTX? Vericel has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M8.81$10.36M$0.031,383.33MeiraGTx$33.28M20.21-$147.79M-$2.32-3.61 Which has more risk & volatility, VCEL or MGTX? Vericel has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Do insiders and institutionals have more ownership in VCEL or MGTX? 67.5% of MeiraGTx shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 7.5% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is VCEL or MGTX more profitable? Vericel has a net margin of 1.25% compared to MeiraGTx's net margin of -484.90%. Vericel's return on equity of 1.09% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.25% 1.09% 0.73% MeiraGTx -484.90%-241.05%-62.93% Does the media refer more to VCEL or MGTX? In the previous week, MeiraGTx had 6 more articles in the media than Vericel. MarketBeat recorded 8 mentions for MeiraGTx and 2 mentions for Vericel. Vericel's average media sentiment score of 0.92 beat MeiraGTx's score of 0.50 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVericel beats MeiraGTx on 10 of the 15 factors compared between the two stocks. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$648.55M$2.90B$5.50B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E Ratio-3.617.8219.9019.84Price / Sales20.21295.68436.90127.27Price / CashN/A41.8337.0657.97Price / Book9.627.868.125.62Net Income-$147.79M-$54.95M$3.16B$248.50M7 Day Performance20.95%6.24%4.40%5.54%1 Month Performance32.44%5.70%4.09%7.52%1 Year Performance107.69%8.08%34.53%22.06% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.4219 of 5 stars$8.37+3.7%$24.00+186.7%+97.3%$648.55M$33.28M-3.61300News CoverageInsider TradeHigh Trading VolumeVCELVericel2.9345 of 5 stars$42.55+2.0%$61.14+43.7%-14.4%$2.10B$237.22M1,418.81300NAMSNewAmsterdam Pharma2.2774 of 5 stars$18.11-2.5%$42.89+136.8%+0.1%$2.08B$45.56M-9.634Positive NewsDNLIDenali Therapeutics4.5856 of 5 stars$13.99-0.8%$33.71+141.0%-32.4%$2.05B$330.53M-5.24430News CoverageAnalyst RevisionKNSAKiniksa Pharmaceuticals International3.5553 of 5 stars$27.67-1.3%$38.80+40.2%+37.0%$2.05B$423.24M-110.68220Analyst UpgradeRXRXRecursion Pharmaceuticals1.9534 of 5 stars$5.06+0.6%$7.00+38.3%-27.6%$2.04B$58.84M-2.86400Trending NewsAnalyst ForecastOptions VolumeAPGEApogee Therapeutics2.8818 of 5 stars$43.43+0.1%$94.60+117.8%-8.1%$2.00BN/A-12.0691News CoverageAnalyst ForecastOptions VolumeHigh Trading VolumeCGONCG Oncology2.3606 of 5 stars$26.00+0.2%$58.67+125.6%-19.0%$1.98B$1.14M-17.2261AGIOAgios Pharmaceuticals4.0684 of 5 stars$33.26-0.6%$58.60+76.2%-11.9%$1.94B$36.50M2.96390INDVIndivior3.2722 of 5 stars$14.74+5.7%$17.00+15.3%-1.1%$1.92B$1.19B-47.551,051High Trading VolumeIRONDisc Medicine3.1624 of 5 stars$52.96-2.8%$96.70+82.6%+11.5%$1.89BN/A-13.5130Positive NewsInsider Trade Related Companies and Tools Related Companies VCEL Competitors NAMS Competitors DNLI Competitors KNSA Competitors RXRX Competitors APGE Competitors CGON Competitors AGIO Competitors INDV Competitors IRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGTX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGTX Stock Alerts